Citius Pharmaceuticals Receives FDA Approval for LYMPHIR(TM) (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR(TM) (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.